TNYA Company Profile and Key Details

Q: Who are the executives of TNYA?

Dr. Saptarsi Haldar M.D.Scientific FounderDr. Sheng DingScientific FounderDr. Kee-Hong Kim Ph.D.Chief Technology OfficerMr. Faraz Ali M.B.A.Chief Executive Officer, Sec. & DirectorDr. Deepak Srivastava M.D.Scientific Founder, Chairman of Scientific Advisory Board & DirectorDr. Whittemore G. Tingley M.D., PH.D.Chief Medical OfficerDr. Benoit G. Bruneau Ph.D.Scientific FounderDr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Bruce R. ConklinScientific FounderDr. Timothy Hoey Ph.D.Chief Scientific OfficerMs. Leone D. Patterson M.B.A.Chief Financial & Bus. Officer

NASDAQ : TNYA

Tenaya Therapeutics

$0.69

0.0308+4.66%

At Close 4:00 PM

63.43

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Tenaya Therapeutics, Inc. (TNYA) stock surged +2.13%, trading at $0.71 on NASDAQ, up from the previous close of $0.69. The stock opened at $0.69, fluctuating between $0.69 and $0.72 in the recent session.

Stock Snapshot

0.6911

Prev. Close

117.59M

Market Cap

0.6911

Day Low

-1.2

P/E Ratio

-0.59

EPS (TTM)

-1.51

Cash Flow per Share

0.69

Open

166.6M

Number of Shares

0.72

Day High

93.57%

Free Float in %

2.04

Book Value

2.48M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	0.68	0.72	0.67	0.69	4.11M
Apr 29, 2026	0.70	0.70	0.66	0.66	3.21M
Apr 28, 2026	0.70	0.73	0.69	0.69	2.62M
Apr 27, 2026	0.70	0.72	0.68	0.70	3.67M
Apr 23, 2026	0.72	0.73	0.68	0.68	3.77M
Apr 22, 2026	0.71	0.75	0.70	0.74	2.91M
Apr 21, 2026	0.74	0.76	0.68	0.69	4.58M
Apr 20, 2026	0.77	0.78	0.74	0.74	2.29M
Apr 17, 2026	0.76	0.81	0.76	0.78	3.29M
Apr 16, 2026	0.76	0.76	0.73	0.75	2.08M
Apr 14, 2026	0.74	0.78	0.73	0.74	2.75M
Apr 13, 2026	0.69	0.74	0.68	0.72	2.57M
Apr 10, 2026	0.74	0.74	0.68	0.69	4.08M
Apr 09, 2026	0.72	0.78	0.71	0.74	3.74M
Apr 08, 2026	0.69	0.73	0.69	0.73	3.66M
Apr 07, 2026	0.68	0.69	0.64	0.67	2.77M
Apr 06, 2026	0.69	0.72	0.66	0.66	3.01M
Apr 02, 2026	0.68	0.70	0.66	0.69	1.5M
Apr 01, 2026	0.70	0.73	0.68	0.68	1.66M
Mar 31, 2026	0.63	0.70	0.63	0.69	2.49M

Contact Details

South San Francisco, CA 94080

United States

https://www.tenayatherapeutics.com 650 825 6900

About Company

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) closed at $0.71 USD, gaining $0.01 (2.13%) from the previous close of $0.69. The stock is currently mid-range between its 52-week high and low $0.36 and $2.35. With a market capitalization of about $117.59 million, Tenaya Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.00). Key stats such as the average daily volume over the past year has been around 4.20 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Tenaya Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Faraz Ali, the company employs approximately 97 people and listed since July 30, 2021. Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -15.17%, SMA50 -16.05%, SMA200 -38.25%). The stock’s 14-day RSI is 38.34 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.08% below its high and over 69.19% above its low. Average 10-day trading volume of 3.38 million shares is below the 3-month average of 3.83 million, indicating normal recent market interest.

Valuation Metrics

Tenaya Therapeutics, Inc. trades at a P/E ratio of -1.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.85 suggesting the stock is closer to book value. The P/FCF stands at -1.66, also below market averages.

Dividend & Fair Value

Tenaya Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.59. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Tenaya Therapeutics, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is -15.57%. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.12. Next year's EPS is expected at -$0.01. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $5.00. The high target offers 1204.35% upside. The low target suggests 624.64% downside. The mean target is $7.00. This offers 914.49% upside. Tenaya Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 11, 2026, missed forecasts by -7.69%. The prior quarter beat by -17.25%. Over the last six quarters, Apple has recorded several small beats. These include -19.59% in November 06, 2024.

Shareholding & Insider Activity

Tenaya Therapeutics, Inc. has 162.98 million shares outstanding. The public float is 152.50 million shares, elevated short interest at 23.49% of float. This equals 13.94 million shares. The short ratio is 3.7 days. Institutional investors hold 50.54% of the float. Insiders own 0.47%. GOEDDEL DAVID V holds 17.86 million shares, Casdin Partners Master Fund, L.P. has 3.22 million shares and Casdin Eli has 1.35 million shares. Over the past six months, insider transactions show net selling. They sold 4.64 million shares across 12 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Tenaya Therapeutics has not generated any revenue. Returns are negative, with ROA at -72.77% and ROE at -89.00%.
On valuation metrics, Tenaya Therapeutics trades at a P/E of -1.16, P/S of 0.00 and P/B of 0.85. The current ratio is 6.84 and quick ratio is 6.84. Debt-to-equity is 0.09, supported by a cash flow-to-debt ratio of -6.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Tenaya Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $8.69M (margin 0.00%). Operating income was - $131.19M (margin 0.0%). Net income was- $124.08M (EPS - $1.68).
The company ended the quarter with $104.64M in cash and short-term investments, a total debt of $12.42M, and net debt of - $33.26M. Total assets were $170.52M, with equity of $139.42M. Financials further reflected weakness, with operating cash flow of - $102.07M, free cash flow of - $103.31M, and capital expenditures of - $1.24M.

Price Forecast & Outlook

Our AI price prediction model suggests that Tenaya Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.16%, with price expected at $0.69 by May 14, 2026, within a range of $0.65 to $0.73 3-Month Outlook: Projected fall of -63.83%, reaching $0.25 by July 29, 2026, with a range of $0.15 to $0.32. 1-Year Outlook: Projected loss of -10.29%, with price at $0.62 by April 30, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares are flat -1.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tenaya Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.06, suggesting 1934.44% upside. Our AI forecast model points to short-term weakness (-0.16% over two weeks), a medium-term fall (-63.83% over three months), and a longer-term loss (-10.29% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Tenaya Therapeutics, Inc. (TNYA) stock price?

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) stock price is $0.71 in the last trading session. During the trading session, TNYA stock reached the peak price of $0.72 while $0.69 was the lowest point it dropped to. The percentage change in TNYA stock occurred in the recent session was 2.13% while the dollar amount for the price change in TNYA stock was $0.01.

TNYA's industry and sector of operation?

The NASDAQ listed TNYA is part of Biotechnology industry that operates in the broader Healthcare sector. Tenaya Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TNYA?

Dr. Saptarsi Haldar M.D.
Scientific Founder
Dr. Sheng Ding
Scientific Founder
Dr. Kee-Hong Kim Ph.D.
Chief Technology Officer
Mr. Faraz Ali M.B.A.
Chief Executive Officer, Sec. & Director
Dr. Deepak Srivastava M.D.
Scientific Founder, Chairman of Scientific Advisory Board & Director
Dr. Whittemore G. Tingley M.D., PH.D.
Chief Medical Officer
Dr. Benoit G. Bruneau Ph.D.
Scientific Founder
Dr. Eric N. Olson Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Bruce R. Conklin
Scientific Founder
Dr. Timothy Hoey Ph.D.
Chief Scientific Officer
Ms. Leone D. Patterson M.B.A.
Chief Financial & Bus. Officer

How TNYA did perform over past 52-week?

TNYA's closing price is 91.97% higher than its 52-week low of $0.36 where as its distance from 52-week high of $2.35 is -70.59%.

How many employees does TNYA have?

Number of TNYA employees currently stands at 97.

Link for TNYA official website?

Official Website of TNYA is: https://www.tenayatherapeutics.com

How do I contact TNYA?

TNYA could be contacted at phone 650 825 6900 and can also be accessed through its website. TNYA operates from 171 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of TNYA are traded daily?

TNYA stock volume for the day was 2.48M shares. The average number of TNYA shares traded daily for last 3 months was 4.2M.

What is the market cap of TNYA currently?

The market value of TNYA currently stands at $117.59M with its latest stock price at $0.71 and 166.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	97
Beta	3
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TNYA Company Profile and Key Details

Tenaya Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways